Brought to you by 
LipoScience gets rights to the Cleveland Clinic's gut flora IP to create heart test
01 May 2012
Executive Summary
With its IPO still pending, LipoScience Inc. (diagnostics) announced it licensed exclusive global rights to IP from the Cleveland Clinic, which the company will use to develop a cardiovascular test based on the gut flora metabolite trimethylamine N-oxide (TMAO).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- MRI, NMR
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
LipoScience gets rights to the Cleveland Clinic's gut flora IP to create heart test
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice